Physion's ElectroMotive Drug Administration technology offers a comprehensive and innovative treatment program for urinary bladder diseases.
NON-MUSCLE INVASIVE BLADDER CANCER
EMDA® Electromotive Drug Administration is a minimally invasive method of enhancing local drug penetration across the urothelium of the bladder and prostatic urethra, resulting in greater quantities of local drug being delivered to a greater tissue depth than is achievable by passive diffusion alone, allowing a better clinical efficacy. EMDA® treatment helps avoid many side effects often associated with systemic administration.
TREATMENT OF BLADDER DISEASES IN AN OUTPATIENT SETTING
- Interstitial Cystitis: results show that the combination of EMDA treatment and bladder cystodistension is an effective first-line treatment.
- Bladder Pain Syndrome: treatment of Bladder Pain Syndrome with EMDA + selected drugs to improve the quality of life of a selected group of patients.
- Recurrent and Persistent UTI: treatment of urinary tract infections with EMDA + antibiotics.
- Hyperactive Bladder: treatment of Hyperactive Bladder with EMDA + oxybutynin plus other drugs.
- Prostatitis
ANDROLOGY
PEYRONIE’S DISEASE
EMDA® (Electro-Motive Drug Administration) system for painless administration of anti-inflammatory drug dexamethasone and anti-collagen verapamil in the plaques
PAIN THERAPHY
- Nerve Entrapment - Inflammation
- Musculoskeletal Inflammations
- RSD Reflex Sympathetic Dystrophy
- Postherpetic Neuropathy
ACCESSORIES
NDO
MITO-IN-CC